Efficacy of Aflibercept (Eylea®) on Choroidal Neovascularization (Type 3)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

26 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-11-25

Study Completion Date

2018-11-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a one-year pilot, interventional, prospective, single arm, non-randomized, multicentric (3 centers) controlled study that aims to evaluate the response of type 3 choroidal neovascularization to treatment by Aflibercept following a classic protocol.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intravitreal Aflibercept for Therapy of Patients With Pseudoxanthoma Elasticum (PXE)

NCT02537054

Pseudoxanthoma Elasticum

COMPLETED PHASE2

Subconjunctival Aflibercept (EYLEA®) for the Treatment of Corneal Neovascularization

NCT02797704

Corneal Neovascularization

TERMINATED PHASE1/PHASE2

Study Evaluating the Efficacy of Aflibercept for the Treatment of NVCI in Young Patients

NCT02257502

Idiopathic Choroidal Neovascularization

COMPLETED PHASE2

Real Life Study in Myopic Neovascularization

NCT03797547

Myopic Choroidal Neovascularisation

UNKNOWN

Intravitreal Aflibercept for Macular Edema Due to Central Retinal Vein Occlusion

NCT06416241

Retinal Vein Occlusion Vascular Occlusive Disease

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Type 3 Choroidal Neovascularization

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Aflibercept

Group Type EXPERIMENTAL

Aflibercept

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aflibercept

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Males or females aged more than 50 years
* Patients with type 3 choroidal neovascularization assessed on FA, ICG and OCT
* Exudation on SD-OCT scans defined by intraretinal cysts or subretinal fluid.
* Best Corrected Visual Acuity at inclusion between 24 and 78 letters (ETDRS)
* Media clarity, pupillary dilation and patient cooperation sufficient to allow fundus photographs of adequate quality

Exclusion Criteria

* Any contraindications as reported in the labelling of Aflibercept (Eylea®): Ocular or periocular infection, Active intraocular inflammation or Hypersensitivity.
* Any previous history of intravitreal injections in the study eye for exudative AMD
* Any secondary chorioretinal anastomosis due to retinal scar or fibrosis
* Any history of vitrectomy
* Media opacities preventing accurate imaging of the retina (cataract)
* Any other retinal disorder possibly associated with type 3 CNV (epiretinal membrane, macular hole)
* Confirmed intraocular pressure ≥25 mmHg or non-stable glaucoma.

Minimum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No